5th Annual Cell Engager Summit

The TCE pipeline is ever-growing and there are multiple different formats, engagers and costimulatory being studied in over 90 trials, with over a hundred projects in the preclinical stage. To treat hematological malignancies, the majority of pharmaceutical and biotech companies are focusing on lymphocyte-restricted tumor-associated antigens such as CD19, CD20, BCMA, CD33, and CD123.

The 5th Annual Cell Engager Summit will discover everything there is to know about the immune cell engager landscape, including clinical successes, prospective response predictors, and cutting-edge immune cell-based engager therapeutic discoveries. To increase safety (lower CRS) and efficacy (higher dose, better tumor penetration/accumulation, lower TMDD) in the solid tumor microenvironment, target tumor antigens (HER2, EGFR, etc.) and change co-stimulatory receptors (CD137/4-1BB, CD28). Use properly proven strategies to address effectiveness issues such as T-cell depletion in solid tumors (alternatives to CD3s, maybe NK engagers), toxicity in hematological malignancies (protease/ph-based cleavage), and toxicity in hematological tumors.

URLs:
Website: https://go.evvnt.com/1508305-0?pid=10018
Tickets: https://go.evvnt.com/1508305-2?pid=10018
Brochure: https://go.evvnt.com/1508305-3?pid=10018

Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

Prices:
Conference + Pre-Conference Day - Drug Developer Rate: USD 4297.00,
Conference Only - Drug Developer Rate: USD 2999.00,
Conference + Pre-Conference Day - Academic Rate: USD 3697.00,
Conference Only - Academic Rate: USD 2599.00,
Conference + Pre-Conference Day - Solution Provider Rate: USD 5297.00,
Conference Only - Solution Provider Rate: USD 3799.00

Speakers:David DiLillo, Senior Director, Immuno-Oncology, Regeneron Pharmaceuticals Inc, David Meininger, Co-Founder and Chief Executive Officer, Link Immunotherapeutics Inc., Diego Ellerman, Staff Scientist I, Genentech Inc, Erin Filbert, Director of Preclinical Research, Apexigen Inc, Gabrielle Leclercq-Cohen, Scientist, F Hoffmann-La Roche Ltd., Hilario Ramos, Head of Immunology, Invenra Inc., Jeffrey Way, Chief Executive Officer, Wyss Institute at Harvard University, Jeremy Myers, Senior Vice President of Research and Development, EvolveImmune Therapeutics, Inc., Julie Bailis, Executive Director, Amgen Inc., Kader Thiam, Senior Vice President of Discovery, Preclinical Models and Services, GenOway, Kate Rochlin, Chief Operating Officer of Operations and Innovation, IN8Bio, Ken Howard,Associate Professor, Aarhus University, Kristan Meetze. Vice President, Cullinan Oncology, Louise Koopman, Senior Scientist, Genmab, Martin Siegemund, Senior Scientist, Pieris Pharmaceuticals, Nicholas Sabarth, Head of Research Laboratory, Biotherapeutics Discovery and Cancer Immunology, Boehringer Ingelheim, Patrick Baeuerle,Chief Scientific Officer, Cullinan Oncology, Shailee Patel, Research Analyst, Beacon Targeted Therapies, Tony arulanandam, Vice President and Head of Preclinical Research, Cytovia Therapeutics, Xavier Michelet, Associate Director Preclinical Pharmacology, MiNK Therapeutics